Quick reads on regulatory developments, clinical operations, career moves, and industry news — published weekly. No noise, no padding.
They are at CROs — Contract Research Organizations. Companies like IQVIA, PPD, Medpace, and Syneos that sponsors hire to run their clinical trials. CROs hire at volume, train systematically, and expose you to multiple therapeutic areas in your first two years. Starting at a CRO is not a lesser path. For most people breaking in without connections, it is the faster one.
Pharma companies develop drugs from chemical compounds. Biotech companies develop products from living organisms — cells, proteins, DNA. The regulatory pathways are different. The manufacturing requirements are different. The risk profile is different. Knowing which side of that line a company sits on changes how you read a job description and evaluate an opportunity.
That is the industry. High risk, long timelines, enormous regulatory scrutiny — and when it works, it changes lives at scale. Every professional in this space is part of that pipeline, whether you are in clinical operations, regulatory affairs, quality, contracts, or finance. That is the work. That is why it matters.
The sponsor owns the drug and funds the development. The CRO executes the clinical program. Understanding both sides of this relationship — what each expects, where tensions arise, and how contracts govern it — makes you significantly more effective on either side of the table.
The CITI Program offers Good Clinical Practice training that every clinical research professional needs. It takes 4–6 hours, costs nothing or very little depending on your institution, and immediately signals baseline competence to any employer in this space. Do it before you apply for anything.
The revised guideline overhauled how risk-based approaches work in practice, introduced new quality management requirements, and clarified sponsor and investigator responsibilities. Here is a plain-language breakdown of what actually changed.
Document Control is often misunderstood as filing. It is not. It is the function that keeps a clinical program inspection-ready — managing the Trial Master File, controlling SOP versions, and ensuring every document is where it needs to be when a regulator walks in.
The outsourcing model is not slowing down. As biotech startups continue to lean on CROs for their full clinical infrastructure, the demand for experienced clinical operations, regulatory, and quality professionals across CRO organizations continues to grow.
Three of the most common contract types in pharma and biotech clinical development — what each one governs, how they relate to each other, and the typical negotiation pressure points that contracts professionals need to know.
Follow Anchor for the latest — posted every week, no noise.
Follow Anchor on LinkedIn →